[Attention to perioperative treatment].
Explore the source record for details and available documents.
Graft Rejection↗
Biomedical subjects
Yuan-Fang Zhang
Publications and source records attributed to Yuan-Fang Zhang.
[Screening urine markers of renal cell carcinoma using SELDI-TOF-MS].
OBJECTIVE: To screen relatively specifical markers in urines from renal cell carcinoma patients using surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) ProteinChip technology. METHODS: Urine samples from 40 renal cell carcinoma (RCC) patients, 40 healthy volunteers and 40 patients with other urogenital diseases were analyzed using IMAC-Cu-3 PoteinChip, which can specifically bind the metal-combining-proteins. Proteomic spectra were generated by mass spectrometry. RESULTS: Four differentially expressed potentially biomarkers were identified with the relative molecular weights of 4020, 4637, 5070, and 5500. The sensitivity for diagnosing RCC was 57.5%, 66.7%, 63.7%, 65%, and specificity was 86.2%, 95%, 82.5% and 75% when the critical points were 2.0, 5.0, 5.0 and 5.0 respectively. CONCLUSIONS: SELDI-TOF-MS ProteinChip technology is a quickly, easy and convenient, and high-throughput analyzing method capable of screening several relatively specific, potential biomarkers from the urines of RCC patients and had better clinical value.
Adult↗
Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.
BACKGROUND: Recent advances in proteomic profiling technologies, such as surface-enhanced laser desorption/ionization mass spectrometry (SELDI), have allowed preliminary profiling and identification of tumor markers in biological fluids in several cancer types and establishment of clinically useful diagnostic computational models. We developed a bioinformatics tool and used it to identify proteomic patterns in urine that distinguish transitional cell carcinoma (TCC) from noncancer. METHODS: Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionization). A preliminary "training" set of spectra derived from analysis of urine from 46 TCC patients, 32 patients with benign urogenital diseases (BUD), and 40 age-matched unaffected healthy men were used to train and develop a decision tree classification algorithm that identified a fine-protein mass pattern that discriminated cancer from noncancer effectively. A blinded test set, including 38 new cases, was used to determine the sensitivity and specificity of the classification system. RESULTS: The algorithm identified a cluster pattern that, in the training set, segregated cancer from noncancer with sensitivity of 84.8% and specificity of 91.7%. The discriminatory pattern correctly identified. A sensitivity of 93.3% and a specificity of 87.0% for the blinded test were obtained when comparing the TCC vs. noncancer. CONCLUSIONS: These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for bladder cancer in high-risk and general populations.
Adult↗
[Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP].
BACKGROUND & OBJECTIVE: Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is an essential enzyme in converting 5'-deoxy-5-fluorouridine (5'-DFUR), and 5-fluorouracil (5-FU) to their active metabolites in vivo, and can be up-regulated by some cytokines such as interleukin-1, and interferon gamma (INFgamma). This study was to observe the regulative effect of INFgamma on expression of PD-ECGF/TP, and its relation with the anti-cancer effect of 5'-DFUR, and 5-FU on RT4 bladder cancer cells. METHODS: PD-ECGF/TP mRNA, and protein expression were determined by reverse transcriptase polymerase chain reaction (RT-PCR), and Western blot analysis, respectively. Cytotoxicity of 5'-DFUR, and 5-FU against RT4 cells was evaluated by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymetho-xyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. RESULTS: Expression levels of PD-ECGF/TP mRNA and protein were elevated in RT4 cells after cultured with INFgamma. INFgamma reduced IC50s of 5'-DFUR [from (9.7+/-0.2) mmol/L to (3.7+/-0.9) mmol/L], and 5-FU [from (130.0+/-21.2) mmol/L to (49.3+/-18.4) mmol/L] in RT4 cells. CONCLUSIONS: INFgamma enhances cytotoxicity of 5'-DFUR, and 5-FU against RT4 cells through induction of PD-ECGF/TP. INFgamma/5'-DFUR or INFgamma/5-FU combination treatment may lead to better chemotherapeutic results in human bladder cancer.
Antineoplastic Agents↗
Efficacy of Prostant on chronic prostatitis in 119 patients.
AIM: To evaluate the efficacy and safety of Prostant in the treatment of chronic prostatitis. METHODS: One hundred and nineteen cases of patients who had been diagnosed of chronic prostatitis were treated by Prostant. The efficacy was evaluated by WBC in EPS and NIH Chronic Prostatitis Symptom Index after a one-month follow-up. RESULTS: After the one-month follow-up, the total improvement rate is 65.5 %, the WBC in the prostatic fluid were reduced from (21+/-20) to (12+/-13)/High-power field (HPF); the symptom index score changed from 12+/-4 to 7+/-5. The pain and voiding score of the symptom index were lowered from 8+/-3 to 5+/-3 and 3.9+/-2.7 to 2.3+/-2.3 respectively. All of above showed great statistic differences (P<0.05). Only 2 cases (1.7 %) reported serious diarrhea. CONCLUSION: The Prostant is effective and safe in the treatment of chronic prostatitis, especially on those cases whose symptom and inflammation in prostatic fluid are not too serious.
Adult↗
[Adolescent varicocele].
The incidence of varicocele in older adolescence varies from 12.4% to 17.8% with an average of 14.7%, similar to the incidence in adult males. Varicocele is associated with testicular growth arrest in adolescents. Varicocelectomy can reverse the testicular growth arrest. But without the testicular growth arrest, prophylactic surgery for every adolescent with varicocele is not advised. Surgery treatment should be offered to: 1. adolescents with testicular growth arrest more than 2 ml of difference between left and right testicle, 2. adolescents with abnormal semen analysis with high-grade varicocele, 3. adolescents with symptoms: pain, heaviness, swelling, 4. adolescents with bilateral varicoceles. Recurrence of the varicocele after surgery treatment can occur in 9% to 16% of adolescents. But rate of recurrence can be kept below 2% in adolescents treated by high retroperitoneal ligation with testicular artery ligation.
Adolescent↗